Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

BGI and H3 Biomedicine to Sequence Pre-Clinical Cancer Models

publication date: Mar 22, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
BGI-Shenzhen and H3 Biomedicine of Cambridge, MA have agreed to develop genomic sequencing data from pre-clinical cancer models. The research is designed to identify and validate recurrent gene mutations that are potential targets for drug therapies. BGI and H3 will share their findings with the global research community after the data analysis is completed. Earlier this week, ChinaBio® Today published an interview with Jun Wang, PhD, the CEO of BGI. Dr. Wang declared that pure science was always the motivating force behind the company’s alliances. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...